Jae Yong Chung

Jae Yong Chung

Auto-generated profile, based on publicly available information

Jae Yong Chung

Department of Pharmacology, Yonsei University College of Medicine, 250 Sungsan-ro, Seodaemun-gu, Seoul 120-752, Korea

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2011 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
SCS K Cho
S K Cho
JYJ S Yoon
J S Yoon
MLM G Lee
M G Lee
DLDong-Hwan Lee
Dong-Hwan Lee
LLL A Lim
L A Lim
PAPark
Park

1 January 2010 in Int. Journal of Clinical Pharmacology and Therapeutics
Verified
Journal Article
Closed access
YLY.J. Lee
Y.J. Lee
MLM.G. Lee
M.G. Lee
LLL.A. Lim
L.A. Lim
SJS.B. Jang
S.B. Jang
JCJ.Y. Chung
J.Y. Chung
This study aimed to evaluate the effect of genetic polymorphisms of SLCO1B1 and ABCB1 on the pharmacokinetics of atorvastatin and its metabolites. 290 Koreans were genotyped for SLCO1B1, ABCB1 and CYP3A5, and 28 subjects were selected for the pharmacokinetic study. Each subject received a single oral dose of 20 mg atorvastatin and blood samples were collected up to 48 hr after dosing. The relationship between the genotypes and atorvastatin pharmacokinetics was examined. For SLCO1B1 genotypes, the mean area under the concentration-time curve from time 0 to infinity (AUC0-infinity) of atorvastatin was 148.2 ng x hr/ml for *15/*15 subjects (n = 3), which was significantly larger than for 1a/*15 and *1b/*15 (n = 8) (80.7 ng x hr/ml, p = 0.0121) and also larger than for *1a/*1a, *1a/*1b and *1b/*1b (n = 17) (66.3 ng x hr/ml, p = 0.0018). The mean AUC0-infinity of 2-hydroxyatorvastatin for *15/*15 was also larger than in *1a/*1a, *1a/*1b and *1b/*1b (p = 0.012). In lactone forms, no significant pharmacokinetic difference was found among the genotypes. For ABCB1 genotypes, the half-lives of atorvastatin, atorvastatin lactone, 2-hydroxyatorvastatin and 2-hydroxyatorvastatin lactone were significantly longer in c.2677TT-c.3435TT (n = 3) vs. c.2677GG-c.3435CC and c.2677GT-c.3435CT (n = 10), yielding p = 0.049, 0.007, 0.007 and 0.007, respectively. This study shows that the SLCO1B1*15 allele may be associated with the individual difference in the AUC0-infinity of atorvastatin whereas the ABCB1 TT-TT diplotype may affect the elimination half-life of the drug in the Korean population.

7 March 2012 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
JCJae Yong Chung
Jae Yong Chung
SCSung Kweon Cho
Sung Kweon Cho
EOEun Sil Oh
Eun Sil Oh
DLDong-Hwan Lee
Dong-Hwan Lee
LLLay Ahyoung Lim
Lay Ahyoung Lim
MPMin Soo Park
Min Soo Park

1 January 2011 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
JCJae Yong Chung
Jae Yong Chung
SJSeong Bok Jang
Seong Bok Jang
YLYoon Jung Lee
Yoon Jung Lee
MPMin Soo Park
Min Soo Park
KPKyungsoo Park
Kyungsoo Park

1 January 2009 in Journal of Korean Society for Clinical Pharmacology and Therapeutics
Verified
Journal Article
Open access
PDF file
JCJae Yong Chung
Jae Yong Chung
Chung JY. J Korean Soc Clin Pharmacol Ther. 2009 Jun;17(1):27-34. https://doi.org/10.12793/jkscpt.2009.17.1.27